de Wolf F - Search Results

1

A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals.

Weverling GJ, Lange JM, de Jong MD, de Weerd H, Goudsmit J, de Wolf F. Weverling GJ, et al. Among authors: de jong md, de weerd h, de wolf f. Antivir Ther. 1996 Dec;1(4):255-63. Antivir Ther. 1996. PMID: 11324828 Clinical Trial.

2

Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men.

Mulder JW, Frissen PH, Krijnen P, Endert E, de Wolf F, Goudsmit J, Masterson JG, Lange JM. Mulder JW, et al. Among authors: de wolf f. J Infect Dis. 1992 Mar;165(3):413-8. doi: 10.1093/infdis/165.3.413. J Infect Dis. 1992. PMID: 1347053

3

Concordance of human immunodeficiency virus detection by polymerase chain reaction and by serologic assays in a Dutch cohort of seronegative homosexual men.

Bruisten SM, Koppelman MH, Dekker JT, Bakker M, de Goede RE, Roos MT, de Wolf F, Coutinho RA, Goudsmit J, Huisman HG. Bruisten SM, et al. Among authors: de goede re, de wolf f. J Infect Dis. 1992 Sep;166(3):620-2. doi: 10.1093/infdis/166.3.620. J Infect Dis. 1992. PMID: 1500745

4

Markers for progression to AIDS during natural infection and antiviral therapy.

Goudsmit J, de Wolf F. Goudsmit J, et al. Among authors: de wolf f. Pathol Biol (Paris). 1992 Nov;39(9):873. Pathol Biol (Paris). 1992. PMID: 1538916 No abstract available.

5

Differences in clinical course in zidovudine-treated asymptomatic HIV-infected men associated with T-cell function at intake.

Gruters RA, Terpstra FG, Lange JM, Roos MT, Harkema T, Mulder JW, De Wolf F, Schellekens PT, Miedema F. Gruters RA, et al. Among authors: de wolf f. AIDS. 1991 Jan;5(1):43-7. doi: 10.1097/00002030-199101000-00006. AIDS. 1991. PMID: 1676272

6

Serologic and immunologic markers in the course of HIV-1 infection.

de Wolf F, Lange JM. de Wolf F, et al. Clin Dermatol. 1991 Jan-Mar;9(1):1-11. doi: 10.1016/0738-081x(91)90110-7. Clin Dermatol. 1991. PMID: 1682023 Review. No abstract available.

7

Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2.

de Wolf F, Meloen RH, Bakker M, Barin F, Goudsmit J. de Wolf F, et al. J Gen Virol. 1991 Jun;72 ( Pt 6):1261-7. doi: 10.1099/0022-1317-72-6-1261. J Gen Virol. 1991. PMID: 1710645

8

Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.

Reiss P, de Wolf F, Kuiken CL, de Ronde A, Dekker J, Boucher CA, Debouck C, Lange JM, Goudsmit J. Reiss P, et al. Among authors: de ronde a, de wolf f. J Acquir Immune Defic Syndr (1988). 1991;4(2):165-72. J Acquir Immune Defic Syndr (1988). 1991. PMID: 1898969

9

Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection.

McRae B, Lange JA, Ascher MS, de Wolf F, Sheppard HW, Goudsmit J, Allain JP. McRae B, et al. Among authors: de wolf f. AIDS Res Hum Retroviruses. 1991 Aug;7(8):637-43. doi: 10.1089/aid.1991.7.637. AIDS Res Hum Retroviruses. 1991. PMID: 1931233

10

Impairment of in vitro immune responses occurs within 3 months after HIV-1 seroconversion.

Teeuwsen VJ, Siebelink KH, de Wolf F, Goudsmit J, UytdeHaag FG, Osterhaus AD. Teeuwsen VJ, et al. Among authors: de wolf f. AIDS. 1990 Jan;4(1):77-81. doi: 10.1097/00002030-199001000-00011. AIDS. 1990. PMID: 1969282

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

349 results

Search Page

Filters